Castle Biosciences, Inc. (CSTL)
| Market Cap | 1.56B |
| Revenue (ttm) | 62.65M |
| Net Income (ttm) | -10.28M |
| Shares Out | 25.06M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $56.24 |
| Previous Close | $62.26 |
| Change ($) | -6.02 |
| Change (%) | -9.67% |
| Day's Open | 61.38 |
| Day's Range | 55.80 - 61.67 |
| Day's Volume | 348,026 |
| 52-Week Range | 29.00 - 107.69 |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Collaborates with the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanAcademyofDermatology--Castle today announced its national sponsorship of the American Academy of Dermatology's (AAD) "Skin Cancer, Take a Hike!"
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer tre...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on May 10,...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AADVMX2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatme...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DNANurses--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatmen...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webina...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer...
The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the st...
Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of Castle Biosciences (NASDAQ:CSTL) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 254.55% year over year to ($0.17), whic...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March 8...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Con...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigment...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP2020--Castle today announced the presentation of data on two of its skin cancer gene expression profile tests during the 57th Meeting of ASDP.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Bi...
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #earnings--Castle today announced its financial results for the third quarter and nine months ended Sept. 30, 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle's president and CEO will present a company overview at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Nov. 19, 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GeneExpressionProfile--Castle Biosciences announced that DecisionDx® DiffDx™-Melanoma is now commercially available.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP--Castle will deliver two poster presentations at The ASDP 57th Virtual Annual Meeting.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the third quarter ended Sept. 30, 2020, after the close of market on Monday, Nov. 9, 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced that it will host an investor webcast to highlight the planned launch of the ConfirmDx®-Melanoma test.
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences Presents Data on DecisionDx-Melanoma at the Virtual European Association of Dermato-Oncology (EADO) Congress.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data were featured in two oral presentations during the 2020 ASDS Virtual Annual Meeting, Oct. 9-11, 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced that Palmetto GBA MolDx has issued a final expanded local coverage determination for the company's DecisionDx®-Melanoma...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery Virtual Annual Meeting.
Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q2 2020 Results - Earnings Call Transcript
About CSTL
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, ... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 25, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol CSTL |
Analyst Forecasts
According to 5 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is 87.17, which is an increase of 55.00% from the latest price.